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Abstract
Background: Head and Neck cancer (HNC) is characterized by significant mortality and morbidity. Treatment is
often invasive and interferes with vital functions, resulting in a delicate balance between survival benefit and
deterioration in quality of life (QoL). Therefore, including prognostic information during patient counseling can be
of great importance. The first aim of this study was to explore HNC patients’ preferences for receiving prognostic
information: both qualitative (general terms like “curable cancer”), and quantitative information (numbers,
percentages). The second aim of this study was to explore patients’ views on “OncologIQ”, a prognostic model
developed to estimate overall survival in newly diagnosed HNC patients.
Methods: We conducted a single center qualitative study by organizing five focus groups with HNC patients
(n = 21) and their caregivers (n = 19), categorized in: 1) small laryngeal carcinomas treated with radiotherapy or laser,
2) extensive oral cavity procedures, 3) total laryngectomy, 4) chemoradiation, 5) other treatments. The patients’
perspective was the main focus. The interview guide consisted of two main topics: life-expectancy and the
prognostic model OncologIQ. All focus groups were recorded, transcribed and coded. Themes were derived using
content analysis.
Results: While all patients considered it somewhat to very important to receive information about their life-
expectancy, only some of them wanted to receive quantitative information. Disclosing qualitative prognostic
information like “the cancer is curable” would give enough reassurance for most patients. Overall, patients thought
life-expectancy should not be discussed shortly after cancer diagnosis disclosure, as a certain time is needed to
process the first shock. They had a stronger preference for receiving prognostic information in case of a poor
prognosis. Prognostic information should also include information on the expected QoL. The pie chart was the
most preferred chart for discussing survival rates.
Conclusions: The participants found it important to receive information on their life-expectancy. While most
patients were enough reassured by qualitative prognostic information, some wanted to receive quantitative
information like OncologIQs’ estimates. A tailor-made approach is necessary to provide customized prognostic
information. A clinical practice guideline was developed to support professionals in sharing prognostic information,
aiming to improve shared decision making and patient-centered care.
Keywords: Prognosis, Life expectancy, Head and neck cancer, Focus groups, Qualitative research, Quality of life,
Survival, Communication, Patient-centered care, Shared decision making
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Background
Head and Neck cancer (HNC) is an aggressive type of can-
cer characterized by significant mortality and morbidity
[1–4]. Treatment is often invasive and interferes with vital
functions such as breathing, swallowing, and speech. In
addition, patients often face psychosocial problems and
experience body image dissatisfaction as a result of the
mutilating procedures [2, 5]. On the one hand physicians
aim for cure and prolonging life, while on the other hand
they strive for optimization of quality of life (QoL). This
often results in a delicate balance between survival benefit
and the functional, and psychosocial disabilities a patient
is willing to accept after treatment. Therefore adequate
counseling of patients including prognostic information
can be of great importance. Previous research focused on
whether or not to disclose the prognosis [6]. More re-
cently the focus has shifted more in-depth to what infor-
mation to provide, and how to do this [6–8]. This is in
line with the increased attention for shared decision mak-
ing (SDM). Patients need to be well-informed before they
can be actively involved in treatment decisions [9, 10]. As
patients may not be able to make well-informed treatment
decisions without understanding their prognosis, provid-
ing prognostic information is a key factor in SDM.
We recently published the results of a qualitative
research, focusing on treatment discussions among HNC
patients and their doctors. We found that in only 6% of
the consultations doctors provided quantitative prognostic
information, by discussing numbers, such as percentages.
In 94% qualitative prognostic information was provided,
by using words such as “curable” and “good prospect”
[11]. The current study is the second step in our qualita-
tive research by exploring HNC patients’ preferences and
views on receiving prognostic information. Relatively little
attention has been paid to this topic. Some cancer patients
want to know everything, while others are overwhelmed
by too much information. Furthermore, each patient
group has its own characteristics and preferences. For ex-
ample, patients with breast cancer are considered to have
high information needs [12]. To our knowledge, there are
no studies published that explore HNC patients’ views on
receiving quantitative prognostic information. Therefore,
research is needed on what these patients want to know
about their prognosis and in which manner they wish this
information to be conveyed to enable better counseling
and patient-centered care.
Physicians are often unable to forecast an individual’s
life-expectancy and tend to overestimate survival [13]
(Hoesseini A, Offerman MPJ, van de Wall - Neecke BJ,
Sewnaik A, Wieringa MH, Baatenburg de Jong RJ: Physi-
cians’ clinical prediction of survival in head and neck cancer
patients in the palliative phase, submitted). This can lead to
concerns of being proved inaccurate and therefore reluc-
tance to discuss the prognosis [14]. Survival rates of cancer
are traditionally based on the TNM-classification of the
tumor. These are however general estimates of a heteroge-
neous group of patients and not tailored to an individual’s
prospect. Prognostic models that include patient specific
predictors, like age and co-morbidity, could help doctors to
provide a more personalized prognosis. Over the last years,
an internally and externally validated prognostic model
named “OncologIQ” has been developed. This model esti-
mates the 1- to 10-year overall survival (OS) of patients
with primary HNC, based on the average treatment effect
[15–17]. Besides tumor location and TNM-classification,
OncologIQ includes age, sex, and the Adult Comorbidity
Fig. 1 An example of OncologIQ’s estimates, as presented during the focus groups
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Evaluation 27 (ACE-27) as prognostic factors for OS (see
also Fig. 1) [15–17]. The benefit of having a HPV-positive
tumor or receiving chemotherapy were added by an adapta-
tion method. This model could support doctors with prog-
nostication during patient encounters, by providing more
personalized estimates of the OS. However, it remains un-
clear if, how, and when this prognostic information should
be shared with HNC patients? Furthermore, how should
one visualize the individual survival estimates and in which
manner should healthcare providers explain the results?
While more prognostic models are developed, there is a
dearth of evidence on the impact of the use of such models
in clinical practice [18], and to what level patients appreci-
ate and understand the information provided [19]. Our
study fills this gap by exploring patients thoughts on
OncologIQ.
The aim of the current study was to explore 1) HNC
patients’ preferences for receiving prognostic informa-
tion, 2) and their views on the prognostic model Onco-
logIQ. By assessing patients’ views on these topics, we
can optimize counseling between physicians and patients.
In addition, a clinical practice guideline on how to use
OncologIQ for individualized prognostic counseling
was developed.
Methods
We conducted a single center qualitative study by organ-
izing five focus groups with HNC patients and their
caregivers between December 2016 and February 2017.
Methods and results are described using the Consoli-
dated Criteria for Reporting Qualitative Research
(COREQ) [20].
Definition of prognosis
In this study we refer to the concept of prognosis from
two different angles:
1) Qualitative information: general terms like “the
cancer is curable”.
2) Quantitative information: numbers or percentages,
like survival rates.
Research team & reflexivity
The research team consisted of three investigators. M.P.J.
Offerman (MO), PhD, is a psychologist and has several
years of experience with focus group research. The second
investigator, A. Hoesseini (AH), MD, is a physician, clin-
ical epidemiologist, and PhD candidate. The third investi-
gator, E.A.C. Dronkers (ED), MD, is also a physician,
clinical epidemiologist, and PhD candidate. MO and AH
conducted the focus groups. There was no relationship
established with the participants prior to the beginning of
the study. Treating physicians were not allowed to attend
the focus groups, so participants would not feel reluctant
to share their thoughts.
Study design
This study was approved by the ethics committee of the
Erasmus Medical Center (MEC-2013-052). After con-
sulting experienced head and oncologists on how the
groups should be selected, we divided patients in five
common treatment groups, which is a reflection of the
patient population we treat in our hospital: 1) small
laryngeal carcinomas treated with radiotherapy or laser,
2) extensive oral cavity procedures, 3) total laryngec-
tomy, 4) chemoradiation, 5) other treatments (local
65 approached
28 informed consent
37 non-responders
18   not interested in participating
12   wants to participate but on another day
5   travel distance
2   due to personal circumstances
7 drop-outs
2   cancelled because of the flu
2   cannot reach the hospital because of a storm
3   reason given (no-show)  
21 included
Fig. 2 Patient selection procedure. Exclusion criteria were: aged 80 years or older; a carcinoma in situ; Korsakoff syndrome or dementia; severe alcohol
and/or drugs abuse; possible recurrent or metastatic disease; recent hospitalization; simultaneous tumor outside of the head and neck region
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resection, neck dissection etc.). In this way, we selected
patients who had a shared experience and thus were
more likely to feel understood by each other. Based on
the theory of social comparison [21], patients with a
similar background feel more recognized and conse-
quently less reluctant to share their thoughts.
Participants were consecutively selected by AH if they
had undergone treatment for HNC in the Erasmus MC
Cancer Institute, 6 to 18months before selection. Patients
were approached by telephone and information about the
content and the working procedure of the focus groups
was given. They were told that we wanted to learn from
their experiences, with a main focus on how they had
experienced the counseling by the healthcare providers. In
order to limit selection bias, specific information on
OncologIQ was not given in advance. Caregivers were en-
couraged to accompany patients. See Fig. 2 for the patient
selection and exclusion criteria. Also, information on non-
participants in shown in Fig. 2. In total 21 patients gave
their informed consent and participated. All focus groups
were held in the same conference room in the Erasmus
MC Cancer Institute. Two volunteers were present during
each focus group to welcome the patients. The volunteers
did not know the patients and did not actively participate
in the focus groups. Data were stored anonymously by
study ID and were only accessible by the research team.
Interview guide
An interview guide was made prior to the start of the
focus groups (see Additional files 1 and 2). The main
topics were 1) life-expectancy, and 2) the prognostic
model OncologIQ. Each topic was first briefly intro-
duced by AH and MO using a PowerPoint presentation
(see Additional files 1 and 2). Subsequently closed-
ended questions, using small cards, were answered by
patients themselves. This enabled patients to react in-
dividually without being affected by the opinion of the
other participants and their caregivers. The closed-
ended questions were followed by open-ended ques-
tions to stimulate the group discussion, and caregivers
were also encouraged to participate to a certain extent,
as patients’ perspective was the main focus. Caregivers
were invited as they are the main source of support for
the patient and are often present during treatment de-
cision consultations. Similar to these conversations, in
the end the patient decides what kind of prognostic in-
formation is shared. OncologIQ was introduced only
after the topic “life-expectancy” was thoroughly dis-
cussed. This order was deliberately chosen as we
wanted to explore life-expectancy unbiased before
introducing the prognostic tool. The model was dem-
onstrated by showing a hypothetical patient with a dif-
ferent kind of tumor than the patients present in the
focus group. The interview guide and presentation
were adjusted once after the first focus group. In this
first focus group we introduced quantitative terms like
“5-year survival” directly after discussing life-
expectancy in qualitative terms such as “curable”. This
resulted in confusion among patients and caregivers.
They interpreted the 5-year survival rate as “being told
you only have five more years left to live” or confused
it with the 5-year follow-up after the diagnosis. There-
fore, we decided to introduce life-expectancy in quali-
tative terms more extensively before the break and
introduce quantitative terms like 5-years survival after
the break in the next focus groups. We also added one
quantitative question on whether the physician should
use a chart when explaining survival rates. After these
adjustments no problems were encountered in focus
group two until five, and therefore no further adjust-
ments were made. All focus groups were digitally re-
corded. The mean duration of the focus groups was 2 h
and 7 min. The focus groups were transcribed by AH
and one of our volunteers.
Data analysis
The grounded theory approach was used to analyze the
data. This implies that the researcher moves back and
forth between the population under study and analysis of
the data, so that an explanatory theory evolves through an
iterative process [22]. Two researchers (AH and MO)
coded all transcripts and discussed the coding for each
group until consensus was reached. Themes were derived
from the coded data by AH and MO individually. These
themes were discussed and if necessary rearranged, start-
ing with one focus group, and adding the others one by
one. When there was no agreement on the themes or on
the matching of quotations with the themes, consensus
was reached after an in-depth discussion. After discussing
the fourth focus group, no new themes were identified
and therefore data saturation occurred. The next step was
verification of the results by the third researcher (ED). She
was given parts of coded transcripts and was asked to
match them with the identified themes, and if deemed
necessary suggest new themes or codes. No new themes
were identified by ED, however some (sub) themes were
rearranged. Finally, one quotation per (sub) theme was
jointly chosen to include in the results section. NVivo 12
was used to manage the data. The participants did not
provide feedback on the findings.
Results
Participants
Table 1 shows an overview of the number of patients
and caregivers in each focus group, and patient charac-
teristics. In total 17 patients (81%) were accompanied by
their caregiver(s). In 15/17 of the cases (88%) this was
a partner. One patient took a sibling with her and one
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patient was accompanied by both his partner and two
children. Education level was categorized according to
the International Standard Classification of Education
[23, 24]. Patients’ age and sex were similar to national
HNC data gathered in the Netherlands Cancer Registry
(NCR) by the Netherlands Comprehensive Cancer
Organization (IKNL) [25]. Patients education level was
more or less similar to a recent study among 2189 con-
secutive HNC patients in our tertiary center (Hoesseini
A, van Leeuwen N, Offerman MPJ, Zhang J, Dronkers
EAC, Sewnaik A, Lingsma, HF, Baatenburg de Jong, RJ:
Predicting survival in head and neck cancer: external val-
idation and update of the prognostic model OncologIQ
in 2189 patients, submitted). This did not apply to mari-
tal status: while in the latter study 28% of patients were
single, in the focus groups only 10% were.
Life-expectancy
After the introduction of the main topic life-expectancy,
we first asked patients the closed-ended question: To
what extent do you think it is important to receive infor-
mation about your life expectancy? (4-point Likert-scale,
Table 1 (a) Number of participants and (b) patient characteristics
Focus groups Patients Caregivers
1. small laryngeal carcinomas treated with radiotherapy / laser 6 (28.6%) 6 (31.6%)
2. extensive oral cavity surgical procedures 2 (9.5%) 2 (10.5%)
3. total laryngectomy 4 (19.0%) 6 (31.6%)
4. chemoradiation 5 23.8%) 3 (15.8%)
5. other treatmentsa 4 (19.0%) 2 (10.5%)
Total no. of participants per focus group (%)b 21 (100%) 19 (100%)
Patient characteristics No. (%) / median (Q1-Q3)
Age, years 65.0 (53.5–68.5)
Age range, years 33–78
Sex
male 12 (57.1%)
female 9 (42.9%)
Tumor localization
larynx 9 (42.9%)
hypopharynx 2 (9.5%)
oral cavity 3 (14.3%)
oropharynx 6 (28.6%)
unknown primary 1 (4.8%)
Tumor stage
I 5 (23.8%)
II 3 (14.3%)
III 5 (23.8%)
IVa 7 (33.3%)
IVb 1 (4.8%)
Marital status
married / durable relationship 19 (90.5%)
single 2 (9.5%)
Education level
lower (primary education or less / lower secondary) 7 (33.3%)
intermediate (upper secondary / post-secondary non-tertiary) 9 (42.9%)
tertiary (short cycle tertiary / bachelor / master / doctoral) 4 (19.0%)
missing 1
Median time between end of treatment and participation in the focus group (Q1 – Q3) 47 weeks (35–64)
a For example neck dissection or local resection
bTwo patients were treated for cancer recurrence by a total laryngectomy, the remaining were treated for a primary head and neck tumor
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“not at all important” to “very important”, see also at-
tachment 1). 62% of patients answered “very important”,
the remaining eight (38%) answered “somewhat import-
ant”. Hereafter, open-ended questions were asked (see
interview guide) to stimulate the group discussion. From
the transcripts of these discussions in total three themes
and 12 subthemes were derived (see Fig. 3 for the code
tree and Table 2 for the contents).
The prognostic model OncologIQ
Table 3 gives an overview of the themes that were
derived from the discussions on OncologIQ (see also
Fig. 3 for the code tree). In addition, several recom-
mendations were shared. Table 4 shows several visual
formats of communication and patients’ preferences
for the selected charts. The pie chart was the most
preferred chart. All patients in focus group two until
five (n = 15) preferred the combination of verbal ex-
planation of survival rates and a visual presentation
with a chart, over a verbal explanation solely. This
was deemed easier to understand.
Discussion
Life-expectancy
Understanding the concept & using a tailor-made approach
To our knowledge, this is the first study offering in-depth
understanding of HNC patients’ preferences for disclosure
of prognostic information, and the use of a prognostic
model during treatment decision consultations.
While all patients considered it somewhat to very
important to receive information about their life-
expectancy, only some of them wanted to receive this
in a specific quantitative manner, like 5-year survival
rates. This is in line with previous research among pa-
tients with advanced or incurable cancer [26, 27]. The
majority of patients wanted to receive prognostic
information from their doctor in general terms, like
‘your cancer can be well treated’. This kind of qualita-
tive information would give these patients enough re-
assurance for the first moment. Even though doctors
generally use the concept 5-year survival rate, partici-
pants often did not understand this concept or con-
fused it with other terms, for example chances of cure,
and thought it had a negative connotation. Overall, lit-
tle is known about patients’ awareness, and under-
standing of prognosis [6]. Previous research stressed
that in some cases cancer patients misunderstand or
fail to absorb the information given, cannot recall the
status of their disease and often overestimate their
survival chances [6, 28–30]. The need for receiving
prognostic information was dependent on different
circumstances. This means that sharing prognostic in-
formation requires a tailor-made approach. Patients
had a stronger preference for quantitative information
like months or survival rates, in the hypothetical case
of cancer recurrence and/or a poor prognosis. This
kind of information would enable them to weigh
whether undergoing a second treatment to prolong
survival would be worth the ‘costs’. Prognostic infor-
mation is not a standalone concept according to pa-
tients and caregivers. Patients also expressed the need
for information about their expected QoL, since this
would be of significant importance in the decision-
making process. Fried et al. asked 226 patients with a
limited life expectancy whether they would choose a treat-
ment with survival, but with severe functional or cognitive
impairment. 74.4% of patients answered they would not
accept severe functional impairment and 88.8% would not
accept cognitive impairment, and thus rather face death
[31]. However, more recent research by Blanchard et al.
among HNC patients showed that they overall prioritize
survival over functional endpoints [32]. Although we did
Fig. 3 Code trees of themes and subthemes derived from the topics 1) life-expectancy and 2) the prognostic model OncologIQ
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not explicitly ask patients to prioritize survival and QoL,
they did however mention that at a certain point the sur-
vival benefits would not weigh against the deterioration in
QoL. On the other hand they mentioned that patients are
prone to keep pushing their boundaries, and increas-
ingly accept functional limitations in order to stay
alive.
In case patients want to receive quantitative informa-
tion, what would be the right timing to share this? Our
focus group results suggest that the right timing and
phasing are of key importance. It seems that life-
expectancy should be best discussed after the conversa-
tion in which the cancer diagnosis is given. According to
most patients and their caregivers, it would be too
stressful to discuss this all at once.
Several patients addressed that it depends on personal
preferences whether a patient wants to receive prognostic
information. While on the one hand some patients gain an
increased sense of control by receiving more information
about their disease and prognosis, others want to receive
very little information. The latter group often wants the
doctor to take control and is not interested in the details on
treatment or prognosis. Receiving unwanted prognostic in-
formation could destroy hope and therefore patients’ needs
should be explored beforehand [33], instead of bluntly con-
fronting them with unwanted information. Who should
take the initiative in exploring prognostic information
needs? While some patients will take the lead, others aren’t
capable or don’t want to. Therefore, according to the par-
ticipants, the healthcare provider should be the one to
introduce the topic, while the patient is given the opportun-
ity to decide whether he or she wants to receive the infor-
mation. This is in agreement with a qualitative research
among advanced cancer patients: most patients and
Table 3 (a) Explanation of (sub)themes, (b) recommendations and quotations, derived from the focus group discussions on topic 2)
prognostic model OncologIQ
Theme Subtheme Quotations
Counseling with the
prognostic model?
How do patients feel and
think about counseling
with OncologIQ?
With model. Some patients want to be counselled with the
prognostic model. They think it gives a clear overview of
their survival chances, and provides a personal estimate of
their survival rates.
It makes it more personal I think. It applies more to you
personally. (caregiver 2, f3)
Without model. Some patients don’t want to be
counselled with the model. They find it too confronting, or
just don’t feel the need to receive counselling with a
prognostic model. Others think the model doesn’t include
enough prognostic factors yet.
If I’m part of the big group, I have more alternative
possibilities.(pt 1, f5)
No preference. Some patients don’t have a specific
preference, as they see both advantages and disadvantages
of receiving prognostics information with a model.
I sit on the fence a little. I think it is more confronting, but
also somewhat more realistic. It is close to home and that
can be frightening. So I am not sure whether I want it like
that. (pt 4, f5)
Recommendations Quotations
Add additional prognostic factors, in order to make the prediction more
individualized.
I actually think it’s pretty unreliable. You should fill in many
more things, like does the patient smoke, drink, and exercise?
(pt 2, f4)
Add treatment modalities if possible. Can you add radiotherapy in this model? (caregiver 1, f2)
Include quality of life as an outcome in the model. This model says nothing about the quality of life. (caregiver 3,
f3)
Provide structural information to make sure every patient is informed about the
possibility to discuss the individual prognosis with OncologIQ.
People should be able to indicate in advance whether they
want to know this or not. (pt 4, f5)
This prognostic information should be given by someone else than the physician, as
the participants thought this task would be too time-consuming and stressful for the
physician. They opted to trust this task to a specialized nurse. In addition, one caregiver
suggested to integrate this in our Healthcare Monitor.
I think it's too much for a doctor. You become a doctor to
help patients, but to really get to know the human psyche is
something else. (caregiver 2, f5)
Take concerns about the health insurance into account. In three focus groups
caregivers shared their concerns about hypothetical consequences for the health
insurance.
Then the premium will increase. (caregiver 2, f3)
Show and explain all variables that are included in OncologIQ. This enables patients
to understand which variables are used to calculate their prediction.
I think you should show the variables. This enables you to see
what the prediction is based on. (pt 3, f3)
Use the 5-year survival rate. When discussing survival rates, participants prefer using
the 5-year survival rates instead of 1- or 10-year survival rates, unless the individual
patient prefers otherwise.
Create the possibility to view OncologIQ in a patient portal.
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Table 4 Visual formats of communication: chart preferences and patient quotations. Patients were asked which figure they would
prefer when talking about life-expectancy*
*First choice nomination resulted in five points, last choice nomination in one point. In total 315 points were divided. Figure 2 until 5 also included captions with
the ‘% died’ versus ‘% survive’, and if applicable captions of the x- and y-axis (not shown in this table)
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caregivers in this study said a physician should offer to dis-
cuss the prognosis, if the option to decline the information
was also provided [34].
Communication skills professional
According to our participants, doctors should be
honest while discussing the prognosis without taking
away hope, and tailor prognostic information after
exploring patients’ needs. The importance of being
realistic and honest while maintaining hope is also
identified in previous literature on patients with
advanced or incurable cancer [35–38]. For example,
Kutner et al. found that while 100% of patients in
their survey wanted honesty from clinicians, 91% also
wanted them to be optimistic [35]. Balancing between
honesty while disclosing prognosis and maintaining
hope can be a challenging task for healthcare pro-
viders [37, 39].
The prognostic model OncologIQ
After fully exploring patients thoughts and believes on the
topic life-expectancy, the prognostic model OncologIQ
was introduced. Some patients would appreciate counsel-
ing with OncologIQ as they thought it was clear and more
personalized, while others were in doubt. Some patients
didn’t want counseling with OncologIQ at all because of
the need to maintain some ambiguity about the future.
This need to maintain ambiguity about outcomes, is also
identified in previous research among advanced or incur-
able cancer patients [27, 33, 36]. Ambiguity could help to
maintain hope and avoids a blunt confrontation with the
facts. Participants shared several recommendations to im-
prove the model. In three focus groups caregivers were
concerned that the monthly health insurance premium
would rise, if the insurance companies would also have ac-
cess to an individuals’ prognostic estimate. Questions on
this topic should be considered when using a prognostic
model for counseling.
Visual formats of communication
Prognosis can be presented in various formats. While pre-
vious research showed that most persons find numbers
and 100-person diagrams easiest to understand [40, 41],
the HNC patients in this study preferred the pie chart.
The pie chart was a favorite because they thought it was
clear at a glance (see Table 4) and less confronting than
some of the other formats. The 100-person diagram was
considered too confronting by both patients and care-
givers. This is in line with previous research that explored
this by using a 100-faces diagram [41]. In addition, Davey
et al. stated that the survival graph was considered
negative, since it showed the constantly increasing
Fig. 4 Clinical practice guideline for individualized prognostic counseling. *Keep the following in mind: do not to discuss life-expectancy in the
same consult in which the cancer diagnosis is discussed but hereafter
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mortality. In the current study, patients’ thoughts on the
survival graph were also mostly negative. They found it
too mathematical, since one must first must interpret the
X- and Y-axis. Davey et al. also tested cancer patients’
understanding of the survival graph: only six out of 26
patients correctly interpreted the graph [41]. Furthermore,
we assessed that the included patients’ preferred to com-
bine verbal explanation with visual prognostic information
over a verbal explanation solely. This is also reported in
previous research on this topic [42]. Furthermore, it
remains unclear as to what extent patients understand the
uncertainty around prognostic models’ estimates [43].
Presenting data uncertainty is difficult and there is no
consensus in literature about the optimal way to commu-
nicate different types of uncertainty [43, 44].
Practice implications: a guideline for individualized
prognostic counseling
OncologIQ could take away physicians reluctance to discuss
the prognosis and reduce ambiguity in case of conflicting
opinions among healthcare professionals by providing indi-
vidual estimates. Previous research showed physicians’ will-
ingness to use prognostic models in end-of-life care, aiming
to improve prognostic confidence [14]. It also enabled physi-
cians’ to take a more directive role in specific cases where
the expected prognosis significantly differs from patients’ ex-
pectations, and it reduced ambiguity in case of conflicting
opinions about prognosis among colleagues [14]. Based on
the results of this focus groups study, especially the recom-
mendations discussed in Table 3, a clinical practice guideline
was developed that includes basic steps for sharing individu-
alized prognostic information (see Fig. 4). While our earlier
published guideline for professional communication focuses
on general aspects of sharing prognostic information with
HNC patients [11], this guideline specifically focuses on how
to share the information provided by the prognostic model
OncologIQ. It could also be used for other similar prognos-
tic models in HNC. Since the term “5-year survival rate”
seemed to confuse patients and caregivers, we recommend
not to use it literally. We asked patients which survival
period would be most appropriate if a patient wants quanti-
tative prognostic information. Most patients preferred five
years, as they deemed two years “too short” and 10 years
“too far ahead”.
Strengths and limitations
One must first listen to patients’ preferences and needs,
to be able to provide patient-centered care. The use of a
qualitative methodology provided us with rich data on
HNC patients’ preferences on these vital but unexplored
topics. However, it is difficult to make assumptions on
its generalizability. This study focused on patients with
HNC in the curative setting. Since each setting has its
own concerns, the generalizability of these results to the
incurable setting is not desirable. Also, our results may
be different in other, non-Western, cultures or countries.
A certain selection bias may have occurred as the in-
cluded patients are willing to participate in a focus group
with other patients and caregivers. In addition, while al-
most one third of the patient population in our center is
single, only 10% of patients in the focus group were. The
presence of family members or other caregivers adds
complexity to prognostic discussions since they may
have different information needs [45]. However, we pur-
posely chose to include caregivers in the focus groups,
as they are also present during the treatment decision
consultation.
Future perspectives
The results of the current study have been used to im-
prove OncologIQ. Recently, the prognostic model has
been updated (Hoesseini A, van Leeuwen N, Offerman
MPJ, Zhang J, Dronkers EAC, Sewnaik A, Lingsma, HF,
Baatenburg de Jong, RJ: Predicting survival in head and
neck cancer: external validation and update of the prog-
nostic model OncologIQ in 2189 patients, submitted). In
the first place because the original model was based on
outdated data as the survival of HNC patients has im-
proved in the past years [46]. The second aim of the up-
date was to test whether adding new prognostic factors
would improve model performance, as recommended
during the focus groups. Also, a visual format for pa-
tients has been developed, including a pie chart of the 5-
year survival rate. The updated model can be found on
www.oncologiq.nl. The next step will be to evaluate the
clinical impact of OncologIQ in a prospective clinical
trial. The primary outcome of this trial is decisional con-
flict among HNC patients who are counselled with and
without the model during treatment decision consulta-
tions. The effect of the use of OncologIQ in our multi-
disciplinary tumor board meetings is also recently
assessed in a pilot study.
A future aim would be to develop a prognostic model
that includes both survival and QoL for HNC patients.
Despite not addressing this future prospective during the
focus groups, several patients stressed the importance of
combining both survival and QoL, rather than focusing
solely on survival. Due to the implementation of our
Healthcare Monitor we will be able to meet this need soon
(Dronkers EA, Baatenburg de Jong RJ, van der Poel EF,
Sewnaik A, Offerman MP: Implementation of a standard-
ized value based clinical support system ‘Healthcare Moni-
tor’ for routine symptom monitoring of head and neck
oncology patients, submitted). With this monitor we are
collecting electronically patient reported outcomes (ePRO)
on physical and psychosocial functioning since 2013, from
intake until the last follow-up visit. In the first place this is
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done to improve patient care and counseling, although
these data could also be used for research purposes.
Conclusions
This study is first in examining HNC patients’ preferences
for disclosure of prognostic information, and the use of a
prognostic model. Overall, the findings of the current study
highlight the importance of exploring patients’ thoughts
and needs, in order to enhance patient-centered care. The
participants found it important to receive information on
their life-expectancy. While disclosing prognostic informa-
tion in general terms like “the cancer is curable” gave
enough reassurance for most patients, some also wanted
numerical information like OncologIQ’s prognostic esti-
mates. A tailor-made approach is necessary to provide this
prognostic information in a customized manner. A clinical
practice guideline was developed to support the healthcare
professional in sharing individualized prognostic informa-
tion, aiming to improve shared decision making.
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